Reviewed by Dr. Akkavich Hannawachok — M.D., Diplomate in Preventive Medicine
Last reviewed: April 2026

Quick answer: Peptide injections for weight loss fall into two very different categories: FDA-approved GLP-1 drugs (semaglutide/Wegovy and tirzepatide/Mounjaro) with strong clinical trial data, and non-GLP-1 peptides (MOTS-C, BPC-157) with promising but early-stage evidence. GLP-1 options produce 15–22% body weight loss in trials. Non-GLP-1 peptides are adjuncts, not replacements. A physician workup determines which — if any — is right for you.

Key points:

  • GLP-1 peptides (Wegovy, Mounjaro) are FDA-approved and have the strongest weight loss evidence — up to 22% body weight in trials
  • Non-GLP-1 peptides like MOTS-C may support metabolic health, but are not primary weight loss tools — they’re adjuncts
  • No peptide works in isolation: diet, exercise, and monitoring are non-negotiable
  • Asian patients often respond at lower GLP-1 doses than Western protocols — titration matters
  • Peptide therapy without proper diagnosis and monitoring is a red flag regardless of where you’re buying it

If you’ve been searching “peptide injections for weight loss” and come away more confused than when you started, that’s not your fault. The term “peptide” is doing enormous heavy lifting in wellness content right now — being used to describe FDA-approved medications with 72-week trial data in one breath, and grey-market research compounds in the next. Let me separate those clearly, because the difference matters enormously to how you should be thinking about this.

First, Let’s Untangle a Confusing Term

Peptides are simply chains of amino acids — smaller than proteins, used by your body as biological signals. The fact that semaglutide and BPC-157 are both “peptides” is technically true the same way that aspirin and chemotherapy are both “medications.” The category name tells you almost nothing useful on its own.

For practical purposes, peptide injections for weight loss split cleanly into two categories with very different evidence profiles and treatment roles.

Category 1: GLP-1 Peptides (The ones with strong evidence)

These are the injections most people are actually asking about when they Google this topic:

  • Semaglutide (Wegovy) and tirzepatide (Mounjaro) — technically peptides, FDA-approved for weight management
  • They work by mimicking gut hormones that signal satiety and slow gastric emptying — your brain gets a sustained “you’re full” signal it doesn’t normally sustain
  • Clinical trials show 15–22% average body weight reduction (STEP and SURMOUNT programs, respectively)
  • These are the weight loss peptide injections with the strongest clinical evidence in existence — by a significant margin

Category 2: Non-GLP-1 Metabolic Peptides (The emerging ones)

These are the compounds more often discussed in longevity and biohacking circles:

Getting clear on this distinction before you do anything else is the single most important thing I can tell you.

How GLP-1 Peptides Actually Work (And Why the Results Are Real)

Close-up of glass peptide vials and a precision syringe on a clean clinical tray for weight loss injections.

Here’s a way I explain GLP-1 drugs to new patients: imagine your hunger has a volume knob. For most people carrying excess weight, that knob is stuck too high — biological signals that should tell you “enough” arrive late, quietly, or not at all. GLP-1 receptor agonists turn that knob down. Meaningfully. Consistently.

More precisely: GLP-1 peptide injections bind to receptors in your brain’s hunger center (hypothalamus), in your pancreas (improving insulin response), and in your gut (slowing how fast food empties from your stomach). The result is reduced appetite, better blood sugar regulation, and a genuine change in how food-motivated you feel — not just willpower over hunger, but a biological reset of the signal itself.

This is why the trial results are real. This isn’t supplement data. The STEP program and SURMOUNT-1 trial are among the largest and most rigorous weight management studies conducted.

What tirzepatide (Mounjaro) adds over semaglutide (Wegovy)

  • Mounjaro targets both GLP-1 and GIP receptors — a dual-agonist mechanism that amplifies the effect beyond GLP-1 alone
  • The SURMOUNT-1 trial (published in The Lancet, 2022) showed up to 22.5% body weight loss at 72 weeks — higher than any semaglutide trial
  • That said, Mounjaro is newer, and its long-term cardiovascular outcome data is still maturing
  • Wegovy, in contrast, added the SELECT trial (published in NEJM, 2023) showing a significant reduction in major cardiovascular events — a meaningful advantage for patients with existing heart disease or elevated CV risk

One practical note: both drugs cause nausea in the early weeks, sometimes vomiting. This isn’t a sign something’s wrong — it’s a direct consequence of slowing gastric emptying, which is part of how they work. Slow titration (starting low, increasing dose gradually over months) is the most reliable way to get through the adjustment period without dropping out.

What About the Other Peptides — MOTS-C, BPC-157, CJC-1295?

I want to be straightforward here, because there’s a lot of noise in this space.

These are real peptides with real biological mechanisms. They’re not scams. But they are not weight loss injections in the way most people searching this topic are hoping — and anyone telling you otherwise is overpromising.

MOTS-C: The mitochondrial one

MOTS-C is a peptide derived from mitochondrial DNA — it supports cellular energy production and appears to improve insulin sensitivity in early studies. Some data suggests relevance to metabolic improvement and exercise performance. But here’s the honest framing: MOTS-C is a metabolic optimizer, not a fat burner. When combined with lifestyle interventions — resistance training, good sleep, controlled carbohydrate intake — it may support better body composition over time. As a standalone injection for weight loss? The evidence isn’t there yet.

CJC-1295 + Ipamorelin: The GH-releasing duo

These two peptides are typically used together because they stimulate your body’s natural growth hormone release through complementary mechanisms. Why does that matter for weight? Growth hormone plays a role in fat metabolism and lean mass preservation. In practice, CJC-1295 and Ipamorelin are most relevant in anti-aging and longevity protocols — particularly for patients already on a GLP-1 program who want to protect muscle mass during weight loss, or for older patients where declining GH contributes to unfavorable body composition changes. They’re not FDA-approved for these uses, and the evidence base is early-stage.

BPC-157 follows a similar pattern — primarily a tissue repair and gut health peptide, with interesting mechanistic data but not a direct weight loss tool.

A note on evidence: Peptide therapy is an emerging area of medicine. The non-GLP-1 peptides discussed here are not FDA-approved for weight loss indications and are used as part of personalized longevity and metabolic protocols based on clinical experience and emerging research. Any use requires individualized physician assessment, baseline bloodwork, and ongoing monitoring. These are not products to self-administer or order online.

At Siam Clinic, non-GLP-1 peptide therapy is offered in the context of broader longevity protocols — not as a weight loss injection program on its own.

Who Is Actually a Good Candidate for Weight Loss Peptide Injections?

This is the section I spend the most time on in actual consultations, because “I want to lose weight” alone doesn’t determine which — if any — peptide injection is right for someone.

Who I’d say yes to (for GLP-1)

  • BMI ≥ 27 with metabolic comorbidities (prediabetes, hypertension, sleep apnea), or BMI ≥ 30 — and for my Asian patients, I apply the Asian-Pacific threshold of BMI ≥ 25 where metabolic risk is often already elevated
  • Patients with prediabetes, insulin resistance, or metabolic syndrome where improving glucose handling is part of the goal
  • People who’ve genuinely committed to diet and exercise changes and haven’t achieved sustainable results — not people who want to skip those steps entirely
  • Anyone willing to treat this as a medical program with monitoring, not a one-time prescription

Who I’d push back on or decline

  • Personal or family history of medullary thyroid cancer or MEN2 syndrome — GLP-1 drugs are contraindicated here, no exceptions
  • History of pancreatitis — the association isn’t fully established, but I won’t take that risk with patients
  • Active or recent history of an eating disorder — GLP-1-driven appetite suppression can mask and worsen disordered eating patterns in ways that are genuinely dangerous
  • Anyone seeking “just an injection” without any lifestyle commitment — I’ll be direct with these patients: the medication changes your appetite biology, but it doesn’t change your habits. When you stop, the biology reverts. The habits are what make results last.

A Note on Asian Patients Specifically

This matters, and it’s something I see managed poorly in clinics that apply Western weight management protocols without adjustment.

First: Asian BMI thresholds for obesity start at 25, not 30. That means patients who don’t look “classically obese” by Western criteria may already carry significant metabolic risk — particularly visceral fat, which is a stronger predictor of metabolic disease than total body fat. I take this seriously when assessing candidates.

Second: in my clinical experience — and this is consistent with emerging literature — Asian patients often respond meaningfully at lower GLP-1 doses than Western protocols are built around. Starting tirzepatide at 2.5mg and semaglutide at 0.25mg and titrating slowly isn’t just cautious practice; it’s often the appropriate therapeutic dose for the duration. Chasing higher doses because a protocol chart says so can mean unnecessary side effects in patients who are already responding well.

Body composition monitoring throughout treatment matters especially here — because a lower starting BMI means less room for error with muscle loss.

What to Realistically Expect — Timeline and Results

Let me set honest expectations, because I’d rather you hear this from me than be surprised later.

For GLP-1 peptide injections, the typical trajectory looks like this: In the first two to four weeks, you’ll notice appetite reduction — sometimes dramatically. You may also experience nausea, which is common and usually improves. By weeks eight to twelve, visible weight loss typically becomes noticeable. By six months on a stable dose, patients on track are usually seeing 10–15% body weight reduction. The 20%+ results from trials take twelve months or more at full therapeutic dose.

One thing I tell every GLP-1 patient upfront: if you stop the medication without building sustainable habits, most studies show 50–70% of lost weight returns within a year of discontinuation. This is not a character flaw — it’s biology. GLP-1 drugs address the appetite signal; your lifestyle changes are what make the result permanent. Planning an exit strategy, or accepting long-term use as a realistic possibility, is part of the honest conversation.

Muscle loss is also a real concern. Research suggests that 25–40% of total weight lost on GLP-1 therapy can come from lean mass without adequate protein intake and resistance training. This is why I track body composition — not just body weight — throughout a program using bioelectrical impedance analysis. A smaller number on the scale means very little if it’s mostly muscle.

For non-GLP-1 peptides, the timeline is longer and the changes more subtle — think body composition shifts over three to six months, improved energy and metabolic markers, rather than dramatic scale movement. These are not the tools you use when significant weight loss is the goal.

Pricing at Siam Clinic (as of April 2026)

GLP-1 peptide injection programs at Siam Clinic are built around the full dose ladders for both medications.

Mounjaro (tirzepatide) is available across its clinical titration range — 2.5mg, 5mg, 7.5mg, and 10mg — with per-dose pricing varying accordingly. Wegovy (semaglutide) follows the standard titration ladder from 0.25mg up to the 2.4mg maintenance dose. Pricing across the full program depends on your starting dose and titration pace; most patients are looking at a multi-month commitment to reach therapeutic dose.

For non-GLP-1 peptides: MOTS-C is available at 5mg per vial in single, three-vial, and six-vial formats. BPC-157 and CJC-1295 are similarly structured. These are priced per vial with program-based options.

Because the right protocol depends entirely on your starting point, the most accurate way to understand cost is through a consultation — we build the program to your needs rather than quote a generic package. Pricing is current as of April 2026 and subject to change.

How We Approach Peptide Therapy at Siam Clinic

The short version: we don’t hand anyone an injection before we understand what we’re treating.

Every weight management patient at Siam Clinic starts with a proper workup. That means body composition analysis using bioelectrical impedance measurement to establish your actual muscle-to-fat ratio — not just your weight. It means a metabolic blood panel: fasting glucose, insulin, HbA1c, lipid profile. And it means a physician consultation where we discuss your goals, your history, and what a realistic program looks like for you specifically.

For GLP-1 therapy — whether Mounjaro or Wegovy — the workup determines which is appropriate and at what starting dose. For non-GLP-1 peptide protocols, the conversation happens in the context of broader metabolic or longevity goals, not as a standalone weight loss injection.

What this means in practice: a consultation at Siam Clinic is a starting point, not a commitment to any particular treatment. If a GLP-1 medication isn’t right for you, I’ll tell you. If lifestyle intervention alone is the better move first, that’s what I’ll recommend.

Frequently Asked Questions

What is the best peptide injection for weight loss?

For weight loss specifically, tirzepatide (Mounjaro) and semaglutide (Wegovy) are the best-evidenced peptide injections available — with 15–22% body weight reduction in major trials. These are the tools with genuine clinical trial data behind them at meaningful scale. Non-GLP-1 peptides like MOTS-C or CJC-1295 are adjuncts for metabolic optimization, not primary fat-loss tools. The “best” option depends on your BMI, cardiovascular risk profile, and treatment goals — which is exactly why a physician assessment should come before any prescription. There’s no universally correct answer independent of your individual picture.

How much weight can you lose with peptide injections?

On GLP-1 peptide injections, clinical trials show approximately 15% body weight loss with semaglutide and up to 22.5% with tirzepatide over 12–18 months when combined with lifestyle intervention. Results vary significantly by individual — some patients respond more, some less, and titration pace affects the timeline. Non-GLP-1 peptides like MOTS-C don’t produce dramatic scale changes. They support metabolic health and body composition gradually over time. Weight loss outcomes on any peptide injection also depend heavily on diet quality, physical activity, protein intake, and adherence to the full protocol.

Are peptide injections for weight loss safe?

GLP-1 peptides (Wegovy, Mounjaro) have well-established safety profiles from large-scale trials involving tens of thousands of patients. Common side effects — nausea, vomiting, constipation — are mostly manageable with slow titration. Serious but rare risks include pancreatitis and a theoretical risk of medullary thyroid cancer, which is why these drugs are contraindicated in patients with a history of MEN2 syndrome or medullary thyroid cancer. Non-GLP-1 peptides have a shorter safety track record in humans — they’re generally well-tolerated in available studies, but require physician supervision and should never be self-administered or sourced without medical oversight.

How long does it take for peptide injections to work for weight loss?

With GLP-1 peptide injections, most patients notice appetite reduction within the first two to four weeks. Visible weight loss typically begins by weeks eight to twelve. Significant results — 10% or more of body weight — are usually seen by the six-month mark. Reaching maximum results takes twelve months or more at therapeutic dose. Non-GLP-1 peptides work on a different and more gradual timeline. Body composition changes from peptides like CJC-1295 or MOTS-C are subtle and typically take three to six months to become measurable — and they’re more about improved metabolic markers and lean mass than scale movement.

What happens when you stop taking weight loss peptide injections?

For GLP-1 peptides, weight regain after stopping is common and well-documented — most studies show 50–70% of lost weight returning within a year of discontinuation when lifestyle habits haven’t been established alongside the medication. This happens because the drug addresses the biological appetite signal, and that signal returns when the drug is gone. This is why I discuss long-term commitment early in any GLP-1 conversation. Having a proper exit strategy — or accepting that ongoing use may be appropriate — is part of realistic program planning. Body composition tracking throughout treatment helps ensure any regain is managed proactively.

Can you get weight loss peptide injections without a prescription in Thailand?

Legally, GLP-1 medications like Mounjaro and Wegovy require a physician’s prescription in Thailand — and for good reason. Obtaining them online or through informal sources creates real risks: counterfeit products are a documented problem in Thailand’s injectable market, dosing without medical guidance leads to avoidable side effects, and there’s no monitoring for contraindications or complications. Non-GLP-1 peptides exist in a regulatory grey zone but still require physician-supervised protocols for safe and appropriate use. Always work through a licensed medical provider for any peptide injection program, regardless of how accessible informal channels appear.

Do peptide injections cause muscle loss?

GLP-1 medications can cause muscle loss alongside fat loss — research suggests 25–40% of total weight lost may come from lean mass without adequate protein intake and resistance training. This is a significant and underappreciated concern. It’s one reason why body composition monitoring throughout a GLP-1 program matters — the scale alone doesn’t tell you whether you’re losing fat or losing muscle. A physician managing your protocol should be tracking muscle mass at regular intervals, not just total body weight. Protein targets and a structured resistance training program are standard parts of any GLP-1 protocol I run.

Are peptides for weight loss the same as Ozempic or Mounjaro?

Ozempic (semaglutide) and Mounjaro (tirzepatide) are technically peptides — chains of amino acids that mimic naturally occurring gut hormones. So yes, in a strict biochemical sense, they are peptides. But the term “peptide therapy” in wellness and biohacking contexts typically refers to non-GLP-1 peptides like BPC-157, MOTS-C, or CJC-1295 — compounds that work through entirely different mechanisms and do not produce the same degree of weight loss. When someone asks about “peptide injections for weight loss,” they may be searching for GLP-1 drugs, non-GLP-1 wellness peptides, or both — without realizing how different the two categories actually are. The evidence levels are not comparable.

Related Services

Mounjaro (Tirzepatide) is the highest-evidence option for patients seeking a peptide injection specifically for weight loss. Its dual GLP-1 and GIP receptor mechanism is what separates it from semaglutide in terms of weight reduction ceiling — the SURMOUNT-1 trial data showing up to 22.5% body weight loss is the most compelling trial outcome in weight management pharmacology to date. I use Mounjaro across its full dose ladder at Siam Clinic, starting at 2.5mg and titrating based on individual response. It’s most appropriate for patients with significant metabolic burden or those who need substantial weight reduction.

Wegovy (Semaglutide) is the other major GLP-1 peptide injection option at Siam Clinic, and for patients with existing cardiovascular disease or elevated CV risk, it’s often the clinically stronger choice despite a somewhat lower weight loss ceiling. The SELECT trial added cardiovascular event reduction to semaglutide’s evidence profile — something tirzepatide’s long-term CV data hasn’t yet matched. For the right patient, Wegovy’s risk-benefit profile is compelling. We discuss the Mounjaro versus Wegovy decision in detail during consultation — there’s a useful comparison article for readers who want to understand the trade-offs before coming in.

Non-GLP-1 Peptide Therapy (MOTS-C, BPC-157, CJC-1295 + Ipamorelin) is available at Siam Clinic as part of personalized longevity and metabolic optimization protocols. I want to be honest about the positioning here: these peptides are not weight loss injections. They’re adjuncts — used alongside GLP-1 therapy when we want to support mitochondrial function, preserve lean mass during weight loss, or optimize body composition as part of a broader anti-aging protocol. Patients who benefit most are those already managing the basics well — diet, exercise, sleep — who want targeted support at the cellular level. This is emerging medicine, and I explain what we know and what we don’t at each consultation.

If you’re trying to figure out which peptide injection — if any — fits your situation, a consultation at Siam Clinic is the right starting point. We run the workup first, then build the protocol. No injection before we know what we’re working with.

📚 References & Evidence (for those interested)
  1. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387:205–216. (SURMOUNT-1 trial)
  2. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023;389:2221–2232. (SELECT trial)
  3. Lee C, et al. MOTS-c: A Mitochondrial-Derived Peptide Regulating Muscle and Fat Metabolism. Cell Metabolism. 2015;21(3):443–454.
  4. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384:989–1002. (STEP 1 trial)
  5. American Diabetes Association. Standards of Care in Diabetes — 2024. Diabetes Care. 2024;47(Suppl 1).
  6. Endocrine Society Clinical Practice Guideline: Pharmacological Management of Obesity. Journal of Clinical Endocrinology & Metabolism. 2015;100(2):342–362.

Medical disclaimer: This article provides general information for educational purposes and does not constitute personalized medical advice. Treatment decisions should be made following consultation with a physician who has examined you and reviewed your medical history. Individual results vary. GLP-1 medications require a valid prescription from a licensed physician. Non-GLP-1 peptides discussed in this article are not FDA-approved for weight loss indications and are used in personalized medical protocols under physician supervision. Siam Clinic provides the treatments referenced in this article.